UPSTREAM BIO, INC. Financing Cash Flow
UPSTREAM BIO, INC. (UPB) reported Financing Cash Flow of $3.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- UPSTREAM BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.53M, a 313.89% increase year-over-year.
- UPSTREAM BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $598.00K.
- UPSTREAM BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.10M, a 99.59% decline year-over-year.
- UPSTREAM BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $760.00K.
- UPSTREAM BIO, INC. net cash provided by (used in) financing activities for fiscal 2025 was $2.44M, a 99.42% decline from fiscal 2024.
- UPSTREAM BIO, INC. net cash provided by (used in) financing activities for fiscal 2024 was $418.91M, a 223.36% increase from fiscal 2023.
- UPSTREAM BIO, INC. net cash provided by (used in) financing activities for fiscal 2023 was $129.55M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.13M 10-Q · filed 2026-08-11 | $4.23M derived: sum of 3 quarters · filed 2026-08-11 | $4.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $598.00K 10-Q · filed 2026-05-13 | $1.70M derived: sum of 2 quarters · filed 2026-05-13 | $2.46M derived: sum of 3 quarters · filed 2026-05-13 | $3.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.86M derived: sum of 2 quarters · filed 2026-03-26 | $2.48M derived: sum of 3 quarters · filed 2026-08-11 | $2.44M 10-K · filed 2026-03-26 |
| 2025-09-30 | $760.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.37M derived: sum of 2 quarters · filed 2026-08-11 | $1.34M 10-Q · filed 2025-11-05 | $271.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $612.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $578.00K 10-Q · filed 2026-08-11 | $271.23M derived: sum of 3 quarters · filed 2026-08-11 | $269.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$34.00K 10-Q · filed 2026-05-13 | $270.61M derived: sum of 2 quarters · filed 2026-05-13 | $268.97M derived: sum of 3 quarters · filed 2026-05-13 | $409.49M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $270.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $269.01M derived: sum of 2 quarters · filed 2026-03-26 | $409.52M derived: sum of 3 quarters · filed 2026-03-26 | $418.91M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $138.88M derived: sum of 2 quarters · filed 2025-11-05 | $148.26M 10-Q · filed 2025-11-05 | $148.13M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $140.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $149.90M 10-Q · filed 2025-08-06 | $149.77M derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | $9.39M 10-Q · filed 2025-05-06 | $9.25M derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | -$133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $129.55M 10-K · filed 2025-03-12 | ||
| 2023-09-30 | $129.68M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |